Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease

• Главные авторы: V. I. Ignatyeva (Автор), S. V. Moiseev (Автор), N. M. Bulanov (Автор), E. A. Karovajkina (Автор), A S. Moiseev (Автор)
• Формат: ‌
• Опубликовано: IRBIS LLC, 2019-01-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Fabry disease (FD) is a severe lysosome storage disease caused by congenital deficiency of the enzyme α-galactosidase A and characterized by the risk of renal failure combined with cardiovascular and CNS complications. According to the currently available information, the early start of enzyme repla...